EMPAPRO LM 1000

About

EMPAPRO LM 1000 combines empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with metformin, a biguanide, offering a comprehensive approach to managing type 2 diabetes. Empagliflozin works by inhibiting the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By blocking this action, it promotes increased glucose excretion in the urine, thereby lowering blood glucose levels independently of insulin.

Metformin, on the other hand, primarily reduces glucose production by the liver, decreases the absorption of glucose from the gastrointestinal tract, and enhances insulin sensitivity in peripheral tissues. The synergistic action of these two agents provides robust glycemic control, addressing multiple pathophysiological defects in type 2 diabetes. This combination is particularly beneficial for adults seeking improved blood sugar management and has demonstrated significant cardiovascular benefits, including a reduction in the risk of cardiovascular death in patients with established cardiovascular disease.

Uses

• Management of type 2 diabetes mellitus in adults.
• To improve glycemic control as an adjunct to diet and exercise.
• To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
• For patients inadequately controlled on empagliflozin or metformin alone.

Directions For Use

Take orally as directed by your physician, usually with meals to minimize gastrointestinal side effects. Do not crush or chew the tablets.

Benefits

• Effective reduction in blood glucose and HbA1c.
• Reduced risk of cardiovascular events and mortality.
• Potential for modest weight reduction.
• Improved insulin sensitivity.
• Dual mechanism of action for comprehensive control.
• Convenient combination therapy.

Side Effects

• Nausea and vomiting
• Diarrhea or constipation
• Abdominal pain or discomfort
• Urinary tract infections
• Genital yeast infections
• Increased urination (polyuria)
• Dizziness or lightheadedness
• Hypoglycemia (especially with other antidiabetic agents)
• Lactic acidosis (rare, but serious with metformin)
• Dehydration
• Ketoacidosis (rare)
• Vitamin B12 deficiency (with long-term metformin use)

Safety Measures

• Alcohol - Avoid excessive alcohol intake as it can increase the risk of lactic acidosis with metformin and may affect blood sugar levels.
• Pregnancy - Generally not recommended during pregnancy. Consult a doctor to discuss risks and alternative treatments.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk. Seek medical advice.
• Liver - Use with caution in patients with liver impairment; metformin is contraindicated in severe hepatic dysfunction due to increased risk of lactic acidosis.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dosage adjustment is required for moderate impairment.
• Lung - No specific contraindications related to lung conditions, but severe respiratory failure can increase lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.